Ci Xiaojiao, Lin Liuyu, Wu Yuqing, Ma Yifang, Lu Jie
Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.
Front Hum Neurosci. 2025 Jul 9;19:1585730. doi: 10.3389/fnhum.2025.1585730. eCollection 2025.
Anti-leucine-rich glioma-inactivated-1 (LGI1) encephalitis is an autoimmune disorder characterized by antibodies that target LGI1 (LGI1-IgG). It typically presents with cognitive impairment, psychiatric disturbances, and faciobrachial dystonic seizures (FBDS). Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is currently recognized as a demyelinating disease of the central nervous system (CNS) mediated by antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG). The co-occurrence of anti-LGI1 encephalitis and MOG-IgG is a rare phenomenon.
We report a case of anti-LGI1 antibody encephalitis combined with MOG-IgG. A comprehensive literature search was conducted using the PubMed and Embase databases. We utilized the following search terms: ("Limbic Encephalitis"[MeSH Terms] OR ("autoimmune encephalitis"[Title/Abstract] OR "AE"[Title/Abstract])) AND ("Myelin-Oligodendrocyte Glycoprotein"[MeSH Terms] OR "demyelinating autoimmune diseases, cns"[MeSH Terms] OR ("MOG-IgG"[Title/Abstract] OR "MOGAD"[Title/Abstract])). The search was constrained to the period from January 1, 2010, to December 31, 2024.
A total of nine papers involving 11 patients were included in the study. Three patients exhibited MOG-IgG in combination with LGI1-IgG. The majority of cases presented with encephalopathic symptoms. Visual changes were observed in a few cases with low titers of serum MOG-IgG or solely in the presence of MOG-IgG in the cerebrospinal fluid (CSF).
The occurrence of anti-LGI1 encephalitis alongside MOG-IgG is a relatively rare phenomenon. The clinical manifestation of encephalopathy in patients with coexisting antibodies presents a significant challenge for clinicians regarding timely diagnosis, highlighting the need for increased vigilance in daily practice.
抗富含亮氨酸胶质瘤失活蛋白1(LGI1)脑炎是一种自身免疫性疾病,其特征是存在靶向LGI1的抗体(LGI1-IgG)。它通常表现为认知障碍、精神障碍和面臂肌张力障碍性癫痫(FBDS)。髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)目前被认为是一种由抗髓鞘少突胶质细胞糖蛋白(MOG-IgG)抗体介导的中枢神经系统(CNS)脱髓鞘疾病。抗LGI1脑炎与MOG-IgG同时出现是一种罕见现象。
我们报告一例抗LGI1抗体脑炎合并MOG-IgG的病例。使用PubMed和Embase数据库进行了全面的文献检索。我们使用了以下检索词:(“边缘性脑炎”[医学主题词]或(“自身免疫性脑炎”[标题/摘要]或“AE”[标题/摘要]))以及(“髓鞘-少突胶质细胞糖蛋白”[医学主题词]或“中枢神经系统脱髓鞘自身免疫性疾病”[医学主题词]或(“MOG-IgG”[标题/摘要]或“MOGAD”[标题/摘要]))。检索范围限定在2010年1月1日至2024年12月31日期间。
该研究共纳入9篇论文,涉及11例患者。3例患者同时出现MOG-IgG和LGI1-IgG。大多数病例表现为脑病症状。少数血清MOG-IgG滴度低或仅脑脊液(CSF)中存在MOG-IgG的病例出现了视觉改变。
抗LGI1脑炎与MOG-IgG同时出现是一种相对罕见的现象。共存抗体患者的脑病临床表现给临床医生的及时诊断带来了重大挑战,凸显了在日常实践中提高警惕的必要性。